Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 4/20 | 1.00 |
| ▸ | PAK4 | O96013 | 4/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | PIM1 | P11309 | 4/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | AKT2 | P31751 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 4/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | STK3 | Q13188 | 4/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19031303 | 1.00 | AKT1 (1.00) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL21094301 | 0.91 | AKT1 (0.83) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL6857775 | 0.86 | AKT1 (0.75) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL2191613 | 0.86 | AKT1 (0.75) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL2191602 | 0.86 | AKT1 (0.75) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL29388655 | 0.86 | AKT1 (0.75) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL29367228 | 0.86 | AKT1 (0.75) | AKT1DAPK3PAK4CHEK2PRKCG | |
| SCHEMBL29386101 | 0.86 | AKT1 (0.75) | AKT1DAPK3PAK4CHEK2PRKCG | |
| A-443654 SCHEMBL19867533 | 0.84 | AKT1 (1.00) | AKT1DAPK3PAK4CHEK2PRKCG | |
| A-443654 SCHEMBL29380923 | 0.84 | AKT1 (1.00) | AKT1DAPK3PAK4CHEK2PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351916-B2 | Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds | CSIR (ZA) | 2019-07-16 | — | — | US | claimed |
| US-20180369264-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-27 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-117479949-A | Methods of producing improved populations of immune cells | 预见疗法有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | disclosed |
| CN-112804994-A | Method for treating myeloproliferative tumors | 卡托斯医疗公司 | 2021-05-14 | — | — | CN | disclosed |
| US-20180369264-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-27 | — | — | US | disclosed |
| WO-2018031407-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | AKT1 98/4885DAPK3 938/4885PAK4 486/4885 |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, JAK1, PDPK1 | AKT1 129/4885DAPK3 786/4885PAK4 206/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | AKT1 129/4885DAPK3 786/4885PAK4 206/4885 |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | AKT1 108/4885DAPK3 416/4885PAK4 610/4885 |
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885DAPK3 611/4885PAK4 314/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | AKT1 153/4885DAPK3 587/4885PAK4 430/4885 |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | CD69, CD209, ICOS | AKT1 4251/4885DAPK3 477/4885PAK4 3620/4885 |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885DAPK3 611/4885PAK4 314/4885 |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IL15, IL15RA, ICOS | AKT1 108/4885DAPK3 416/4885PAK4 610/4885 |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | AKT1 108/4885DAPK3 416/4885PAK4 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.